SRAMF.US Sisram Medical Ltd
- Market cap
- USD 25.8M
- P/E
- 1.8x
- P/B
- 0.05x
- ROE
- 4.0%
- Dividend yield
- 29.22%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is SRAMF.US undervalued?
Graham numberThe Graham number of Sisram Medical Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sisram Medical Ltd fundamental analysis
No fundamental analysis for Sisram Medical Ltd yet.
Sisram Medical Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sisram Medical Ltd
Sisram Medical Ltd, together with its subsidiaries, engages in the research, design, development, manufacture, sale, and marketing of medical aesthetics and dental equipment, home-use devices, injectables, and cosmeceutical products in the Asia Pacific, North America, Europe, the Middle East, Africa, and Latin America. The company offers a portfolio of products and treatments for clinical aesthetic indications, including hair removal, skin rejuvenation, acne and acne scars, …
Full company profileSisram Medical Ltd financial statements
Sisram Medical Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 118M | 137M | 154M | 174M | 162M | 294M | 354M | 359M | 349M | 365M |
| Gross Profit | 62.2M | 73.2M | 82.3M | 95.9M | 90.3M | 167M | 202M | 220M | 217M | 215M |
| Operating Income | 20.5M | 20.9M | 24.5M | 26.1M | 20.4M | 50.6M | 55.4M | 42.1M | 35.7M | 32.6M |
| EBITDA | - | 27.0M | 29.5M | 35.3M | 28.2M | 56.0M | 58.4M | 53.4M | 52.3M | 49.1M |
| Net Income | 8.06M | 11.0M | 21.8M | 20.8M | 13.3M | 31.2M | 40.2M | 31.5M | 25.1M | 19.0M |
| EPS | - | 0.02 | 0.05 | 0.05 | 0.03 | 0.07 | 0.09 | 0.07 | 0.05 | 0.04 |
| Balance Sheet | ||||||||||
| Total Assets | 279M | 347M | 350M | 393M | 432M | 530M | 556M | 614M | 627M | 657M |
| Total Liabilities | 239M | 53.6M | 36.0M | 67.9M | 99.9M | 127M | 123M | 144M | 142M | 154M |
| Shareholders' Equity | 40.5M | 293M | 314M | 326M | 332M | 402M | 431M | 452M | 464M | 480M |
| Cash & Short-term Investments | 18.1M | 38.1M | 105M | 108M | 116M | 153M | 81.5M | 70.6M | 70.2M | 71.0M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 16.0M | 17.1M | 16.2M | 21.0M | 25.7M | 32.4M | 22.0M | 43.9M | 33.1M | 9.40M |
| Capital Expenditure | 1.04M | 769K | 1.27M | 3.17M | 9.27M | 2.97M | 64.3M | 8.57M | 18.1M | 2.58M |
| Free Cash Flow | - | 14.4M | 15.0M | 17.9M | 16.5M | 29.4M | -42.3M | 35.4M | 14.9M | 6.82M |
| Ratios | ||||||||||
| ROE | 19.9% | 3.8% | 7.0% | 6.4% | 4.0% | 7.8% | 9.3% | 7.0% | 5.4% | 4.0% |
| ROA | 2.9% | 3.2% | 6.2% | 5.3% | 3.1% | 5.9% | 7.2% | 5.1% | 4.0% | 2.9% |
| Net Profit Margin | 6.8% | 8.1% | 14.2% | 12.0% | 8.2% | 10.6% | 11.3% | 8.8% | 7.2% | 5.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sisram Medical Ltd dividends
- Dividend yield
- 29.22%
- Forward dividend
- 0.01 USD
- Payout ratio
- 39.6%
- Ex-dividend date
- Aug 26, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 7.54M | 0.02 | 39.6% |
| 2024 | USD 9.45M | 0.02 | 37.6% |
| 2023 | USD 10.5M | 0.02 | 33.4% |
| 2022 | USD 9.33M | 0.02 | 23.2% |
| 2021 | USD 4.19M | 0.01 | 13.4% |
| 2020 | USD 6.27M | 0.01 | 47.0% |
| 2019 | USD 5.63M | 0.01 | 27.1% |
| 2018 | USD 5.63M | 0.01 | 25.8% |
| 2017 | USD 5.63M | 0.01 | 51.0% |
| 2016 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Sisram Medical Ltd
- Insiders 71.72%
- Institutions 0.02%
- Public & others 28.26%
- Shares outstanding 467M
- Free float 133M
Sisram Medical Ltd company profile
- Company name
- Sisram Medical Ltd
- Ticker
- SRAMF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,043
- Fiscal year end
- December
- Address
- Ofek Building 15, Caesarea, Israel, 3079895
- Phone
- 972 4 627 5357
- Website
- sisram-medical.com
About Sisram Medical Ltd
Sisram Medical Ltd, together with its subsidiaries, engages in the research, design, development, manufacture, sale, and marketing of medical aesthetics and dental equipment, home-use devices, injectables, and cosmeceutical products in the Asia Pacific, North America, Europe, the Middle East, Africa, and Latin America. The company offers a portfolio of products and treatments for clinical aesthetic indications, including hair removal, skin rejuvenation, acne and acne scars, trans-epidermal delivery, face and body contouring, cellulite treatment, stretch marks, vascular and pigmented lesions, pigmentation and skin resurfacing, fat grafting, dermal facial fillers, skin tissue remodeling, injectables, personal care, aesthetic dentistry, hydradermabrasion, blepharoplasty (nonsurgical eyelid lift), liposuction, feminine health, and sexual rehabilitation. It also engages in pharmaceutical research and development activities. The company offers its products under the Alma, LMNT, Copulla, Profhilo, and Aliaxin brands. Sisram Medical Ltd was founded in 1999 and is headquartered in Caesarea, Israel.
Sisram Medical Ltd management
7- Mr. Lior Moshe DayanExecutive Chairman · born 1970
- Mr. Jiahong Li M.B.A.Co-CEO, CFO & Executive Director · born 1980
- Mr. Eyal Ben DavidCo-CEO & President · born 1981
- Hui FanInvestor Relations Director
- Ms. Tal Burgan RosenC.S.M.O
- Ms. Orit SegalC.H.O
- Ms. Qianli FangCompany Secretary · born 1994